Patent applications published 12 January 2011

Published: 4-Feb-2011

Selected patent applications from the weekly European Patents Bulletin


  • Methods for treating a condition characterised by dysfunction in protein homeostasis
    The Scripps Research Institute 2271213*

  • Pharmaceutical solutions and method for solubilising therapeutic agents
    Particle Sciences 2271214*

  • Use and compsn for treating dementia
    Chase Pharmaceuticals 2271218*

  • Nerve repair with a hydrogel and optional adhesive
    University of Florida Research Foundation 2271312*

  • Novel solid forms of bendamustine hydrochloride
    Cephalon 2271315*

  • Fenofibrate dosage forms
    Elan Pharma International; Fournier Laboratories Ireland 2271316*

  • Method for manufacturing acid pellets
    Boehringer Ingelheim International 2271317*

  • Pharmaceutical depot comprising N-(5-T-(cyclopropylamino)-arbonyl]-2-methylphenyl]-3-fluoro-4-(pyridin-2-ylmethoxy)-benzamide
    AstraZeneca 2271318*

  • Formulation with a reduced hygroscopicity
    Bayer Technology Services 2271319*

  • Raloxifene pharmaceutical formulations
    Dr Reddy’s Laboratories Ltd; Dr Reddy’s Laboratories Inc 2271320*

  • Pharmaceutical compsn 271
    AstraZeneca 2271321*

  • Encapsulation of biologically active agents
    Glaxo Group 2271322*

  • Encapsulation of biologically active agents
    Glaxo Group 2271323*

  • Encapsulation of biologically active agents
    Glaxo Group 2271324*

  • Methods and use of inducing apoptosis in cancer cells
    Cytotech Labs 2271325*

  • Modulation of fibroblast activity
    The University of Leicester 2271326*

  • Pharmaceutical compsn comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction
    Merck Patent 2271327*

  • Antiseptic compsns for the treatment of infections
    Alsa Pharmaceuticals 2271328*

  • Methods, compsns and kits for treating pain and pruritis
    President and Fellows of Harvard College; The General Hospital Corp 2271329*

  • Extended release hydrocodone acetaminophen and related methods and uses thereof
    Abbott Laboratories 2271330*

  • Compsns and devices for antisepsis and anticoagulation
    Gottardi, Waldemar 2271331*

  • Use of compounds in the treatment of Tau-induced cytotoxicities
    Bioalvo-Seriços, Investigaçao E Desenvolvimento Em Biotecnologia 2271332*

  • Induction of proliferation, effector molecule expression, and cytolytic capacity of HIV-specific CD8+ T cells
    The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 2271333*

  • Methods of treating fibrotic disorders
    Paloma Pharmaceuticals 2271334*

  • Improved statin production
    DSM IP Assets 2271335*

  • Process for extracting coumarins
    Darome 2271336*

  • Beta-turn peptidomimetic cyclic compounds for treating dry eye
    Mimetogen Pharmaceuticals 2271337*

  • Methods for treating neurological disorders with imidazolium and imidazolinium compounds
    Agency for Science, Technology & Research, Singapore 2271338*

  • ONO1910.NA enhances chemotherapeutic agent activity in drug-resistant tumours
    The Johns Hopkins University 2271339*

  • Pharmaceutical preparation comprising stephaglabrin sulphate for treating demyelinating diseases of the nervous system and for promoting restoration of the myelin sheath of nerve fibres
    Zakrytoe Aktsionernoe Obschestvo “Biogen Technologies” 2271340*

  • Specific inhibitors for vascular endothelial growth factor receptors
    Nova Southeastern University 2271341*

  • Salts of 2-substituted quinolines
    Institut De Recherche Pour Le Developpement 2271343*

  • Methods of treating disease-induced ataxia and non-ataxic imbalance
    University of South Florida 2271344*

  • HCV NS3 protease inhibitors
    Merck Sharp & Dohme 2271345*

  • Monocyclic CGRP receptor antagonists
    Merck Sharp & Dohme 2271346*

  • Administration of benzodiazepine compsns
    Hale Biopharma Ventures 2271347*

  • Oral and injectable formulations of tetracycline compounds
    Paratek Pharmaceuticals 2271348*

  • Compsns and methods for skin care
    Antipodean Pharmaceuticals 2271349*

  • Compsns and methods for immunotherapy
    Cognate3 2271350*

  • Compsns and methods for treating viral infections
    Spring Bank 2271351*

  • Compsns and methods for treatment of neoplastic disease
    Innate Therapeutics 2271352*

  • Vaccine
    GlaxoSmithKline Biologicals 2271360*

  • Method and vaccine for optimising the specific immune responses
    Université de Lausanne 2271361*

  • Novel antibodies against cancer target block tumour growth, angiogenesis and metastasis
    The Regents of the University of California 2271362*

  • Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
    Baxter Healthcare SA; Baxter Healthcare Inc; Halozyme 2271363*

  • Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
    IBC Pharmaceuticals 2271364*

  • Regulation of fatty acid transporters
    The Ludwig Institute for Cancer Research 2271365*

  • Antibodies to Clostridium difficile spores and uses thereof
    3M Innovative Properties 2271366*

  • Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
    Cedars-Sinai Medical Centre 2271368*

  • Rasagilene mesylate particles and process for the preparation thereof
    Actavis Group 2271612*

  • Hydroxymethylcyclohexyl amines
    Grünenthal 2271613*

  • Method for the continuous synthesis of an N-acylated compound, and equipment for implementing said method
    Societe D’Exploitation De Produits Pour Les Industries Chimiques Seppic 2271614*

  • Novel process for preparation of iopromide
    LG Life Sciences 2271615*

  • Sulphoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
    Ecolab 2271616*

  • Substituted 4-hydroxy-N-(4-hydroxyphenyl) indoles as estrogenic agents
    Glaxo Group 2271617*

  • Pharmaceutical compounds
    Astex Therapeutics 2271618*

  • Compounds and compsns as modulators of GPR119 activity
    IRM LLC 2271619*

  • Compsns and methods for inhibition of hepatocyte growth factory receptor C-Met signalling
    The United States of America, as represented by the Secretary, Department of Health and Human Services 2271620*

  • Pyridyl derivatives as CFTR modulators
    Vertex Pharmaceuticals 2271621*

  • Heteroaryl derivatives as CFTR modulators
    Vertex Pharmaceuticals 2271622*

  • Perpropionic acid compsn that is stable in a basic medium
    Arkema France 2271623*

  • Iminopyridine derivatives and use thereof
    Takeda Pharmaceutical Company 2271624*

  • Tetrahydroisoquinolines, pharmaceutical compsns containing them, and their use in therapy
    Abbott; Abbott Laboratories 2271625*

  • Tetrahydrophenanthidinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerisation inhibitors
    Janssen Pharmaceutica 2271626*

  • Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
    The General Hospital Corp 2271627*

  • Benzimidazole derivatives as calcium channel blockers
    Actelion Pharmaceuticals 2271628*

  • Substituted pyrimidin-5-carboxamides 281
    AstraZeneca 2271629*

  • Compounds and compsns as protein kinase inhibitors
    IRM LLC 2271630*

  • Inhibitors of protein kinases
    Portola Pharmaceuticals 2271631*

  • 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
    F Hoffmann-La Roche 2271632*

  • Method for producing chiral, epoxy ketones
    Studiengesellschaft Kohle 2271633*

  • Modulators of dopamine neurotransmission
    NSAB 2271634*

  • Modulators of dopamine neurotransmission
    NSAB 2271635*

  • Modulators of dopamine neurotransmission
    NSAB 2271638*

  • Piperidine derivatives as CGRP receptor antagonists
    Bristol-Myers Squibb 2271640*

  • Pyridinyl inhibitors of hedgehog signalling
    Genentech; Curis 2271642*

  • Compounds
    Glaxo 2271643*

  • Substituted piperidines as therapeutic compounds
    Novartis 2271644*

  • Compounds and compsns as kinase inhibitors
    IRM LLC 2271645*

  • Apoptosis signal-regulating kinase 1 inhibitors
    Takeda Pharmaceutical 2271646*

  • C2-fluoro substituted piperazine linked pyrrolo[2,1-C][1,4] benzodiazepine dimers and a process for the preparation thereof
    Council of Scientific and Industrial Research, India 2271647*

  • Isoxazoline linked pyrrolo [2,1-C][1,4]benzodiazepine hybrids as potential anticancer agents and the process for preparation thereof
    Council for Scientific and Industrial Research, India 2271648*

  • Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-A]pyrimidines, methods for preparation and uses thereof
    Wyeth 2271649*

  • Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
    Bristol-Myers Squibb 2271650*

You may also like